A comparative study of Xalatan and Xalacom (Pfizer, USA) efficacy in the treatment of pseudoexfoliative glaucoma
The purpose of this study was to compare the efficacy of Xalatan (Pfizer, USA) and Xalacom (Pfizer, USA) in pseudoexfoliative glaucoma therapy. We observed 41 patients (53 eyes) with PEG, 16 of them were men and 25 women. Treatment period was 24 months. The main group (20 patients, 28 eyes) instilled Xalatan, the comparison group (21 patients, 25 eyes) instillated Xalacom once before bedtime (8 p. m.). In the Xalatan group, IOP decreased from 23.75 ± 0.576 mm Hg at baseline to 18.93 ± 0.337 mm Hg at 6 Month visit, and increased again up to 22.00 ± 0,542 mm Hg by the end of 24 months period. In the Xalacom group, IOP decreased from 22.00 ± 0.552 at baseline to 19.67 ± 0.47 at 6 Months visit and did not increase significantly to the 24 Month visit. Glaucoma stabilization was registered in both groups. MD index improved at 12 Months visit from –5.16 ± 0.61 to –4.21 ± 0.66, without significant changes till Visit 24 Month in the Xalatan group. MD index improved for the entire period of observation from –5.57 ± 0.64 to 4.82 ± 0.69 in the Xalatan group. These results allow us to recommend Xalatan and Xalacom as medications of choice for PEG treatment, especially taking into consideration possible risk of glaucomatous optic neuropathy progression.